MilestonesSeptember 2015

Research roundup

LDI Director honoured with Award of Excellence

Dr. Roderick McInnes, Director of the Lady Davis Institute at the JGH, has received the 2015 Award for Excellence in Human Genetics Education from the American Society of Human Genetics. The award was also presented to his co-authors of the sixth, seventh and eighth editions of the seminal textbook, Human Genetics in Medicine.

Nearly 60 genetics education programs worldwide use the textbook, in levels ranging from undergraduate to graduate and professional study. It is also used in diverse contexts, including medical, nursing, public health, speech and language, and dental programs.

Dr. McInnes has contributed to scientific understanding of the molecular basis of retina and eye development, as well as identifying genes and processes associated with retinal degeneration. His laboratory focuses on neuronal processes—specifically, identifying molecular mechanisms that promote or inhibit the inherited degeneration of neurons, and elucidating the roles of two multifunctional proteins in the regulation of ion channels.

Dr. McInnes has served on numerous educational committees since the 1970s, and in 1988 he launched the Clinician Scientist Training Program at the Research Institute of the Hospital for Sick Children in Toronto. He has also taught genetics at the medical and graduate levels, and he has supervised graduate students, postdoctoral fellows and visiting scholars, serving on their advisory and examination committees throughout.

Dr. McInnes has sat on various committees of the American Society of Human Genetics since 1989. He was a member of the Board of Directors from 2004 to 2007 and from 2009 to 2012, as well as President in 2010. He was an associate editor of the American Journal of Human Genetics from 1994 to 1996.

 

Dr. Mark Wainberg

Dr. Mark Wainberg

AIDS pioneer receives career award

Dr. Mark Wainberg, head of HIV/AIDS research in the Lady Davis Institute at the JGH and Director of the McGill AIDS Centre, has received the Canadian Society of Microbiologists’ Murray Award for Career Achievement—the Society’s premier honour for senior researchers. A plaque was presented to Dr. Wainberg at the organization’s annual general meeting in Regina earlier this year.

 

Research grants in hypertension and venous thromboembolism

Four researchers and JGH physicians have received seven-year Foundation grants from the Canadian Institutes of Health Research, from the first round of the “live pilots” of the Foundation Scheme.

Dr. Ernesto L. Schiffrin

Dr. Ernesto L. Schiffrin

 

Dr. Ernesto L. Schiffrin, who is JGH Physician-in Chief, Director of the JGH Cardiovascular Prevention Centre, and Vice-Chair (Research) of the Department of Medicine at McGill University, has been granted a total of $3,164,111 as Principal Investigator for the research project, “Vascular Remodeling in Hypertension and Cardiometabolic Disease: From Mice to Humans.”

Dr. Susan R. Kahn

Dr. Susan R. Kahn

 

Dr. Susan R. Kahn, Director of the JGH Thrombosis Program and the Centre of Excellence in Thrombosis and Anticoagulation Care, has received a total of $2,050,824 as Principal Investigator for the research project, “Improving Long-Term Outcomes After Venous Thromboembolism.”

Individuals, corporations and foundations interested in supporting the work of Dr. Schiffrin and Dr. Kahn can direct their contributions to the Hemovascular and Epidemiology research sections, respectively, of the Lady Davis Institute. For more information or to donate, please visit the JGH Foundation online or call 514-340-8251.

Dr. Howard Chertkow

Dr. Howard Chertkow

 

Dr. Howard Chertkow, co-founder and Director of the JGH/McGill Memory Clinic, and Scientific Director of the Canadian Consortium on Neurodegeneration in Aging, is using $1,695,053 for the project, “Typical and Atypical Alzheimer Disease: Salivary Tau Biomarkers, Therapy with Neuromodulation, and Disease Subtypes.”

Dr. Laurent Azoulay

Dr. Laurent Azoulay

 

Dr. Laurent Azoulay, a project leader in the the Lady Davis Institute at the JGH, has received $852,701 to advance his project, “Cancer Pharmacoepidemiology: A Population-Based Assessment of the Risks of Prescription Drugs in Vulnerable Populations.”

 

LDI researchers share in breast cancer grants

Four LDI researchers—Dr. Moulay Alaoui-Jamali (left), Dr. William Foulkes (third from left), Dr. Mark Basik (fifth from left) and Dr. Michael Witcher (third from right)—join colleagues from other institutions, officials from the Quebec Breast Cancer Foundation, and dignitaries in announcing grants for breast cancer research.

Four LDI researchers—Dr. Moulay Alaoui-Jamali (left), Dr. William Foulkes (third from left), Dr. Mark Basik (fifth from left) and Dr. Michael Witcher (third from right)—join colleagues from other institutions, officials from the Quebec Breast Cancer Foundation, and dignitaries in announcing grants for breast cancer research.

Four researchers from the Lady Davis Institute at the JGH are among nine recipients of strategic funding awards from the Quebec Breast Cancer Foundation, worth $500,000 per person over four years.

Dr. Moulay Alaoui-Jamali

Dr. Moulay Alaoui-Jamali

More Quebec women are affected by breast cancer than any other form of the disease. However, thanks to advances in science, the five-year survival rate has reached 88 per cent.

Dr. Moulay Alaoui-Jamali is developing an innovative approach to prevent metastasis.

Dr. Mark Basik

Dr. Mark Basik

 

Dr. Mark Basik is analyzing genetic data to predict the risk of post-surgery recurrence.

Dr. Wilvliam Foulkes

Dr. William Foulkes

 

Dr. William Foulkes is trying to identify mutations to explain why certain Quebec families are at a higher risk of developing breast cancer.

Dr. Michael Witcher

Dr. Michael Witcher

 

Dr. Michael Witcher is studying a new therapeutic target for preventing metastasis.

Individuals, corporations and foundations interested in supporting the work of Dr. Alaoui-Jamali, Dr. Basik, Dr. Foulkes and Dr. Witcher can direct their contributions to the Cancer research section of the Lady Davis Institute. For more information or to donate, please visit the JGH Foundation online or call 514-340-8251.

 

Grants for three staffers in the LDI and JGH

Research awards have been presented to members of JGH staff:

  • Dr. Brent Richards

    Dr. Brent Richards

    Brent Richards, a researcher in the Lady Davis Institute (LDI) at the JGH, and a member of the Division of Endocrinology, has received the William Dawson Award from McGill University for a five-year term.

  • Sarit Assouline, of the LDI and the Division of Hematology, has been given a Junior 2 award for a three-year term by the Quebec Research Fund – Health Care.
  • Osama Roshdy, of the Division of Dermatology, has secured a research grant from the Canadian Dermatology Foundation.

Individuals, corporations and foundations interested in supporting the work of Dr. Richards, Dr. Assouline and Dr. Roshdy can direct their contributions to the Epidemiology and Cancer research sections, respectively, of the Lady Davis Institute. For more information or to donate, please visit the JGH Foundation online or call 514-340-8251.

 

Promotions for researchers

Dr. Andrew Mouland

Dr. Andrew Mouland

Dr. Andrew Mouland, Head of the HIV-1 RNA Trafficking Laboratory in the Lady Davis Institute (LDI) at the JGH, has been promoted to full Professor of Medicine, Microbiolology and Immunology at McGill University.

Dr. Brett Thombs, a psychosocial researcher in the LDI, has been promoted to full Professor in McGill’s Department of Psychiatry.

Dr. Marie Hudson, an epidemiology researcher in the LDI, and a member of the JGH Department of Rheumatology, has been promoted to Associate Professor with tenure at McGill.

 

Awards support prostate cancer research

Two innovative scientists, who are working on novel projects in the Lady Davis Institute at the JGH, have been awarded Movember Discovery Grants by the Movember Foundation and Prostate Cancer Canada. The grants, worth $200,000 per project, could make a significant difference in prostate cancer research.

Dr. Jian Hui Wu

Dr. Jian Hui Wu

Dr. Jian Hui Wu and his team are proposing to develop new chemical compounds to stimulate the immune system to fight prostate cancer cells. STING is a protein structure that has already demonstrated an ability to stimulate an aggressive anti-tumour response, and Dr. Wu’s team hopes to promote this response in patients. Until now, compounds that activate STING in mice have had a dramatic anti-tumour effect, but the particular compound that is being used cannot activate human STING.

Dr. Ivan Topisirovic

Dr. Ivan Topisirovic

Dr. Ivan Topisirovic, in collaboration with a team of international experts, has designed an “artificial prostate” to help understand how cells in two compartments of the prostate (the epithelium and stroma) communicate. Although communication is a normal function, it can influence the development and spread of prostate cancer.

Dr. Topisirovic is also designing tools to monitor and control cell communication. This could give physicians a better idea of when to postpone radical treatments in cases that are less aggressive. It may also help to block communication to improve existing treatments in cases of advanced prostate cancer.

Individuals, corporations and foundations interested in supporting the work of Dr. Drs. Wu and Dr. Topisirovic can direct their contributions to the Cancer research section of the Lady Davis Institute. For more information or to donate, please visit the JGH Foundation online or call 514-340-8251.

 

Big win for LDI’s Annual ReportLDI Annual Report 2012

The Annual Report of the Lady Davis Institute (LDI) at the JGH, edited by Research Communications Officer Tod Hoffman, has won an international award for production and design. Sharing the honours are the LDI and CommDesign, winners of a 2015 Gold Hermes Creative Award in a global competition administered by the Association of Marketing and Communications Professionals.

Previous article

JGH News honoured among Canada’s top hospital magazines

Next article

Pioneering effort to apply novel biotechnology to cancer research

No Comment

Leave a comment